Vico Therapeutics Revenue and Competitors

Leiden,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Vico Therapeutics's estimated annual revenue is currently $9.2M per year.(i)
  • Vico Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • Vico Therapeutics has 46 Employees.(i)
  • Vico Therapeutics grew their employee count by 2% last year.

Vico Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Scientific Officer & Site HeadReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Lead Clinical Project ManagerReveal Email/Phone
5
Manager CMCReveal Email/Phone
6
Manufacturing chemistReveal Email/Phone
7
Senior ScientistReveal Email/Phone
8
Scientist PK & assay developmentReveal Email/Phone
9
Research Technician Molecular BiologyReveal Email/Phone
10
Molecular analystReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Vico Therapeutics?

Bringing knowledge, experience and science together to discover, develop and deliver therapies for CNS disorders. Vico was founded in Q4 2019 by the highly experienced entrepreneurs Luc Dochez and Josh Mandel-Brehm and seasoned scientists Dr. Judith van Deutekom and Dr. Gail Mandel with strong academic reputations and vast industry experience. Together with a team of skilled scientists and drug development professionals, Vico's focus is on development of RNA modulating therapies for rare neurological disorders, with initial focus on SCA – Spinocerebellar ataxia, HD – Huntington's disease and RETT syndrome.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$9.2M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vico Therapeutics News

2022-04-17 - Curebase selected to launch a clinical investigation of a digital ...

Alex Therapeutics develops software as a medical device (SaMD) ... The company's shares (VICO) are listed on Nasdaq Stockholm's main market.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.4M5510%N/A
#2
$9.5M613%N/A
#3
$12.9M6548%N/A
#4
$10.1M6535%N/A
#5
$16M6632%N/A